Advagraf® with or without an induction therapy for de novo kidney-transplant recipients

References

• Ekberg H, Tedesco-Silva H, Demirbas A, ELITE-Symphony Study; et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007; 357(25):2562–2575.
   PubMed Web of Science ®Google Scholar
• Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9(8):1876–1885.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Extended-release tacrolimus: a review of its use in de novo kidney transplantation. Drugs. 2014;74(17):2053–2064.
   PubMed Web of Science ®Google Scholar
• Barraclough KA, Isbel NM, Johnson DW, et al. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs. 2011;71(12):1561–1577.
   PubMed Web of Science ®Google Scholar
• Wlodarczyk Z, Ostrowski M, Mourad M, et al. Tacrolimus pharmacokinetics of once- versus twice-daily formulations in de novo kidney transplantation: a substudy of a randomized phase III trial. Ther Drug Monit. 2012;34(2):143–147.
   PubMed Web of Science ®Google Scholar
• Crespo M, Mir M, Marin M, et al. De novo kidney transplant recipients need higher doses of Advagraf® compared with Prograf® to get therapeutic levels. Transplant Proc. 2009;41(6):2115–2117.
   PubMed Web of Science ®Google Scholar
• Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant. 2007;7(3):595–608. Erratum in: Am J Transplant. 2007;7(6):1682.
   PubMed Web of Science ®Google Scholar
• Silva HT Jr, Yang HC, Meier-Kriesche HU, et al. Long-term follow-up of a phase III clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/ MMF,and cyclosporine/MMF in de novo kidney transplant recipients. Transplantation. 2014;97(6):636–641.
   PubMed Web of Science ®Google Scholar
• Jones-Hughes T, Snowsill T, Haasova M, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. Health Technol Assess. 2016;20(62):1–594.
   Web of Science ®Google Scholar
• Albano L, Banas B, Klempnauer JL, Optimising immunoSuppression After Kidney transplantation with ADVAGRAF® Study Group; et al. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96(10):897–903. Erratum in: Transplantation. 2014;97(6):38.
   PubMed Web of Science ®Google Scholar
• Krämer BK, Charpentier B, Bäckman L, Tacrolimus Prolonged Release Renal Study Group; et al. Tacrolimus once daily (ADVAGRAF®) versus twice daily (PROGRAF®) in de novo renal transplantation: a randomized phase III study. Am J Transplant. 2010; 10(12):2632–2643.
   PubMed Web of Science ®Google Scholar
• Masutani K, Tsuchimoto A, Haruyama N, et al. Protocol biopsy findings in living donor kidney transplant patients treated with once-daily or twice-daily tacrolimus formulation. Transplant Proc. 2014;46(2):395–399.
   PubMed Web of Science ®Google Scholar
• Han DJ, Park JB, Kim YS, et al. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen. Transplant Proc. 2012 Jan;44(1):115–117.
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2):333–340.
   PubMed Web of Science ®Google Scholar
• Mourad G, Glyda M, Albano L, et al. Incidence of posttransplantation diabetes mellitus in de novo kidney transplant recipients receiving prolonged-release tacrolimus-based immunosuppression with 2 different corticosteroid minimization strategies: ADVANCE, a randomized controlled trial. Transplantation. 2017;101(8):1924–1934.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33 Suppl.1:S11.24.
   Web of Science ®Google Scholar
• Gatault P, Kamar N, Büchler M, et al. Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study. Am J Transplant. 2017;17(5):1370–1379.
   PubMed Web of Science ®Google Scholar
• Malvezzi P, Jouve T, Rostaing L. Use of everolimus-based immunosuppression to decrease cytomegalovirus infection after kidney transplant. Exp Clin Transplant. 2016;14(4):361–366.
   PubMed Web of Science ®Google Scholar
• Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials. Clin J Am Soc Nephrol. 2017;12(8):1321–1336.
   PubMed Web of Science ®Google Scholar
• Piao SG, Lim SW, Doh KC, et al. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions. Transplantation. 2014;98(1):22–28.
   PubMed Web of Science ®Google Scholar
• Huh KH, Lee JG, Ha J, RECORD Study; et al. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial. Nephrol Dial Transplant 2017;32(8):1415–1424.
   PubMed Web of Science ®Google Scholar
• Rummo OO, Carmellini M, Rostaing L, et al. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus. Transpl Int. 2017;30(1):83–95.
   PubMed Web of Science ®Google Scholar
• Yamanaka K, Kakuta Y, Nakazawa S, et al. Induction Immunosuppressive therapy with everolimus and low-dose tacrolimus extended-release preserves good renal function at 1 year after kidney transplantation. Transplant Proc. 2016;48(3):781–785.
   PubMed Web of Science ®Google Scholar
• Devresse A, Avettand-Fenoel V, Scemla A, et al. De Novo use of everolimus reduces late-onset cytomegalovirus primary disease occurring after antiviral prophylaxis discontinuation in kidney transplant recipients. Am J Transplant. 2017;17(suppl 3):1–848.
   Google Scholar